한국형 양극성 장애 약물치료 알고리듬 2014: 신체질환이 동반되었을 경우
- Alternative Title
- Korean Medication Algorithm for Bipolar Disorder 2014: Medical Comorbidity
- Abstract
- OBJECTIVE
The third revision of Korean Medication Algorithm Project for Bipolar Disorder was performed in 2014 in order to provide more proper guideline for clinicians. In this study, we undertook a survey of expert opinion to help clinical decisions in medical comorbidities.
METHODS
The questionnaire to survey the expert opinion of medication for bipolar disorder was completed by the review committee consisting of 64 experienced psychiatrists. This survey was composed of 56 main questionnaires of which the contents covered from overall treatment strategies to treatment strategies under the specific situations. The executive committee analyzed the results and discussed the final production of algorithm.
RESULTS
In bipolar patients with cardiovascular, diabetic, or hepatic comorbidities, aripiprazole was first-line treatment strategy. In case of renal comorbidity accompanying bipolar disorder, aripiprazole, valproate, and quetiapine were preferred. Valproate was recommended as the first-line strategy in case of bipolar disorder with cerebrovascular diseases.
CONCLUSION
This study provided information about the consensus among experts in regard to treatment strategies for bipolar disorder in the medically ill.
- All Author(s)
- M. D. Kim
; J. G. Lee
; B. H. Yoon
; Y. E. Jung
; J. H. Jeong
; I. Sohn
; S. H. Shim
; Y. S. Woo
; D. I. Jon
; J. S. Seo
; Y. C. Shin
; K. J. Min
; W. M. Bahk
- Issued Date
- 2014
- Type
- Article
- Keyword
- Bipolar disorder; Medical comorbidity; Pharmacotherapy; Algorithm
- Publisher
- 대한정신약물학회
- ISSN
- 1017-5717
; 2092-5700
- Citation Title
- 대한정신약물학회지
Korean Journal of Psychopharmacology
- Citation Volume
- 25
- Citation Number
- 4
- Citation Start Page
- 155
- Citation End Page
- 160
- Language(ISO)
- kor
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2675
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.